Gerresheimer reshapes its pharmaceutical packaging business

Gerresheimer is continuing to reshape its portfolio as the pharmaceutical packaging specialist responds to challenging market conditions and seeks to concentrate resources on higher-value healthcare and drug-delivery applications.

The company has taken several major strategic steps during 2026, including the planned divestment of Centor and its global Primary Packaging Plastics business. The transactions are intended to strengthen Gerresheimer’s balance sheet, reduce leverage and create a more focused portfolio centred on pharmaceutical, biotech and medical technology customers.

Primary Packaging Plastics business set for sale

Gerresheimer agreed in July to sell Centor and its global Primary Packaging Plastics operations to funds advised by Apax Partners. The two businesses have a combined enterprise value of approximately €1.5 billion and include 16 production sites employing around 2,400 people across nine countries.

The Centor transaction is expected to close by the end of the 2026 financial year, while the Primary Packaging Plastics sale is scheduled for completion during the first half of financial year 2027, subject to customary approvals.

Portfolio moves towards higher-value applications

The divestments underline Gerresheimer’s strategy of focusing more heavily on specialised pharmaceutical packaging, drug-delivery systems and medical technologies rather than maintaining a broad portfolio of conventional primary plastic packaging.

Demand for high-value solutions such as injection systems, prefillable syringes, vials and advanced containment technologies continues to be influenced by growth in biologics, injectable medicines and increasingly complex therapies.

Market conditions remain demanding

Gerresheimer has nevertheless faced a challenging operating environment. Project delays, production ramp-up costs and weaker demand in some segments have placed pressure on profitability, leading the company to revise its expectations for 2026.

The group has responded by tightening working-capital management, controlling investment and adjusting production volumes. Preliminary first-quarter results showed revenue of €524 million and adjusted EBITDA of €66 million.

Free cash flow becomes a major priority

Cash generation has become one of the central elements of Gerresheimer’s restructuring efforts. First-quarter free cash flow improved by more than €100 million year on year, moving from negative €141 million to negative €32 million.

The company attributes the improvement to more selective capital expenditure, lower inventory build-up and stricter working-capital management. Proceeds from the planned divestments are also expected to significantly reduce debt and improve the group’s financing structure.

Pharmaceutical packaging remains strategically important

Despite near-term market pressure, pharmaceutical packaging continues to offer attractive long-term growth opportunities. Ageing populations, biologic medicines, injectable therapies and increasingly stringent product-protection requirements are supporting demand for specialised packaging systems.

Manufacturers are also facing growing expectations around sustainability, traceability, regulatory compliance and compatibility with automated filling operations, increasing the technical complexity of pharmaceutical packaging.

Gerresheimer prepares for a more focused future

The company expects operating performance to strengthen during the second half of 2026 as restructuring measures progress and production efficiency improves. Its portfolio changes suggest that future growth will increasingly depend on higher-margin products and integrated solutions for pharmaceutical and biotech customers.

For the broader packaging sector, Gerresheimer’s transformation illustrates how major suppliers are reassessing their portfolios as healthcare packaging becomes more specialised, capital-intensive and closely connected to drug-delivery technology.